Latest Articles
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Defense World
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Defense World
Published: March 2, 2026, 6:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat
Published: Feb. 27, 2026, 4:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance
Published: Feb. 27, 2026, 4:47 p.m.
Acrivon Therapeutics hosts webcast on ACR-368 trial at ESGO Congress - Investing.com
Acrivon Therapeutics hosts webcast on ACR-368 trial at ESGO Congress Investing.com
Published: Feb. 27, 2026, 2:18 p.m.
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference The Manila Times
Published: Feb. 24, 2026, 1:18 p.m.
The role of probiotics in the treatment of endometriosis (ProMetrioS): a randomized double-blinded placebo-controlled cross-over trial.
ProMetrioS is a randomized, blinded, placebo-controlled cross-over trial investigating the effect of a specific multispecies probiotic in patients with endometriosis. The aim of this clinical trial is to determine whether …
Published: Feb. 20, 2026, midnight
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Solve PI3K Resistance - HIT Consultant
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Solve PI3K Resistance HIT Consultant
Published: Feb. 18, 2026, 5:03 p.m.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Priva - PharmiWeb.com
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Priva PharmiWeb.com
Published: Feb. 18, 2026, 4:05 p.m.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - PharmiWeb.com
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement PharmiWeb.com
Published: Feb. 18, 2026, 4:05 p.m.
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider
Published: Feb. 18, 2026, 3:28 p.m.
Link copied to clipboard!